早期非小细胞肺癌立体定向体部放疗:ASTRO循证指南执行摘要
美国放射肿瘤学会(ASTRO)组建工作组,围绕4个关键问题对早期非小细胞肺癌(NSCLC)的立体定向体部放疗(SBRT)进行系统文献综述,并按预设共识方法制定推荐。指南就中心型肿瘤的分割方案及标准风险可手术患者中手术与SBRT的选择给出强共识推荐,对>5 cm肿瘤、全肺切除术后、T3胸壁侵犯、多原发及再程放疗后挽救等情形给出条件性推荐。
要点
- 中心型肿瘤的分割方案及标准风险可手术患者的手术与SBRT选择获强共识推荐。
- 肿瘤>5 cm、全肺切除术后、T3胸壁侵犯、多原发肺癌及放疗后挽救治疗仅为条件性推荐。
- 中等及低质量证据领域应重视临床试验入组与前瞻性数据登记。
核心结论
- SBRT在早期NSCLC治疗中具有重要作用,尤其适用于医学上不可手术、其他治疗选择有限的患者。
- 所有病例均应进行医患共同决策,确保患者了解SBRT相关风险、副作用及可用的替代治疗。
研究设计与样本
- ASTRO组建工作组,对4个关键问题进行系统文献综述,并按预设共识方法制定推荐,证据质量与推荐强度采用ASTRO批准的工具分级。
主要发现
- 已完成随机试验较少,但基于大量一致的发表文献,多个问题形成了强共识推荐。
- 中等及低质量证据领域凸显了临床试验入组及前瞻性数据登记的作用。
关键数值与推荐
- 强共识推荐涵盖中心型肿瘤的分割方案,以及标准风险、医学上可手术的早期NSCLC患者中手术与SBRT的选择。
- 条件性推荐涉及>5 cm肿瘤、既往全肺切除术患者、伴胸壁侵犯的T3肿瘤、同时性多原发肺癌及既往放疗后的挽救治疗。
临床怎么用
- 对医学上不可手术的早期NSCLC患者可考虑SBRT。
- 中心型肿瘤应按指南推荐的分割方案实施SBRT。
- 标准风险且医学上可手术患者需在手术与SBRT之间进行共同决策。
- 上述证据质量中低的情形宜优先考虑临床试验入组或前瞻性登记。
局限性
- SBRT相关随机试验完成较少。
- >5 cm肿瘤、全肺切除术后、T3胸壁侵犯、多原发肺癌及再程放疗后挽救等领域证据质量仅为中等或低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline presents evidence-based recommendations for stereotactic body radiation therapy (SBRT) in challenging clinical scenarios in early-stage non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: The American Society for Radiation Oncology convened a task force to perform a systematic literature review on 4 key questions addressing: (1) application of SBRT to operable patients; (2) appropriate use of SBRT in tumors that are centrally located, large, multifocal, or unbiopsied; (3) individual tailoring of SBRT in "high-risk" clinical scenarios; and (4) SBRT as salvage therapy after recurrence. Guideline recommendations were created using a predefined consensus-building methodology supported by American Society for Radiation Oncology-approved tools for grading evidence quality and recommendation strength. RESULTS: Although few randomized trials have been completed for SBRT, strong consensus recommendations based on extensive, consistent publications were generated for several questions, including recommendations for fractionation for central tumors and surgery versus SBRT in standard-risk medically operable patients with early-stage NSCLC. Lower quality evidence led to conditional recommendations on use of SBRT for tumors >5 cm, patients with prior pneumonectomy, T3 tumors with chest wall invasion, synchronous multiple primary lung cancer, and as a salvage therapy after prior radiation therapy. These areas of moderate- and low-quality evidence highlight the importance of clinical trial enrollment as well as the role of prospective data registries. CONCLUSIONS: SBRT has an important role to play in treating early-stage NSCLC, particularly for medically inoperable patients with limited other treatment options. Shared decision-making with patients should be performed in all cases to ensure the patient understands the risks related to SBRT, the side effects, and the alternative treatments available.
引用
- Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017. PMID: 28596092. doi:10.1016/j.prro.2017.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。